(2S,3S)-2-Amino-3-(2,2-diphenylethyl)pentanedioic acid selective group 2 metabotropic glutamate receptor antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 7, 1998, Pages 765-770

  Escribano, Ana ^a   Ezquerra, Jesús ^a   Pedregal, Concepción ^a   Rubio, Almudena ^a   Yruretagoyena, Belén ^a   Baker, S Richard ^b   Wright, Rebecca A ^b   Johnson, Bryan G ^b   Schoepp, Darryle D ^b  

^a ELI LILLY AND COMPANY   (Spain)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (2,2 DIPHENYLETHYL)PENTANEDIOIC ACID; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR; UNCLASSIFIED DRUG; 2 AMINO 4 (2,2 DIPHENYLETHYL)PENTANEDIOIC ACID; 2-AMINO-4-(2,2-DIPHENYLETHYL)PENTANEDIOIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; CYCLIC AMP; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GLUTAMIC ACID; GLUTAMIC ACID DERIVATIVE; METABOTROPIC RECEPTOR 2; PHOSPHATIDYLINOSITOL;

ARTICLE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; REACTION ANALYSIS; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING COMPETITION; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; FOREBRAIN; METABOLISM; PHYSIOLOGY; RAT; SYNTHESIS;

ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CYCLIC AMP; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMATES; GLUTAMIC ACID; INDICATORS AND REAGENTS; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOLS; PROSENCEPHALON; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032492485     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00091-2     Document Type: Article

References (13)

1. 1 Collindridge, G. L.; Lester, R. A. Pharmacol. Rev., 1989, 40, 143-210.
2. 2 Cunningham, M. D.; Ferkany, J. W.; Enna, S. J. Life Sci., 1994, 54, 135-148.
3. 3 Hollmann, M.; Heinemann, S. Annu. Rev. Neurosci., 1994, 17, 31-108.
4. 4 Nakanishi, S.; Masu, M. Annu. Rev. Biophys. Biomol. Struct., 1994, 23, 319-348.
5. 5 Nakanishi, S. Science, 1992, 258, 597-603.
6. 6 Pin, J. P.; Duvoisin, R. Neuropharmacology, 1995, 34, 1-26.
7. 7 Wermuth, C. G.; Mann, A.; Schoenfelder, A.; Wright, R. A.; Johnson, B. G.; Burnett, J. P.; Mayne, N G.; Schoepp, D. D. J. Med. Chem., 1996, 39, 814-816.
8. 8 (a) Ezquerra, J.; Pedregal, C.; Rubio, A.; Yruretagoyena, B.; Escribano, A. M.; Sánchez-Ferrando, F., Tetrahedron, 1993, 49, 8665-8678.
9. (b) Ezquerra, J.; Pedregal, C.; Micó, I.; Nájera, C. Tetrahedron: Asymmetry, 1994, 5, 921-926.
10. 9 Ezquerra, J.; Pedregal, C., Rubio, A.; Yruretagoyena, B.; Carreño, M. C.; Escribano, A.; Garcia Ruano, J. L. J. Org. Chem., 1995, 60, (9), 2925-2930.
11. 10 Structures of 1j and 1o are depicted: (formula presented)
12. 11 Wright, R. A.; McDonald, J. W.; Schoepp, D. D. J. Neurochem., 1994, 63, 938-945.
13. 12 Schoepp D.D.; Johnson B.G.; Salhoff C.R., Valli M.J.; Desai M.A.; and Monn J.A.Neuropharmacology, 1995, 34, 843-850.